Inovio Pharmaceuticals Inc (INO)

[Lakers_w]

Oct 8, We've (CEPI) launched a $200M call on Mar 31, 2021 to fund vaccines that are broadly protective against SARS-CoV-2 variants and other coronaviruses.
The first partnerships to be made through this Call will be announced in the coming weeks.

Inovio has applied for 4802 CEPI grant. 4802 should be a front runner. Ditto BARDA.

Coronaviruses have now demonstrated their pandemic potential. The SARS and MERS coronaviruses are associated with case fatality rates of 10%-35% (5-16 times worse than COVID-19) and we know that coronaviruses circulate widely in animal reservoirs.

While the world has made great advances in vaccines development against the coronavirus that causes COVID-19, variants of concern (such as B.1.1.7; B.1.351, and P.1) now pose a threat to this progress. They spread rapidly, can reinfect people who have been infected before, and they are rendering our countermeasures—including our vaccines and monoclonal-antibody treatments—less effective.

The increased transmissibility of these variants could result in a reversal in the global downward trends in transmission seen in recent weeks resulting in a renewed burden on health systems, and more deaths.

CEPI has already begun development of vaccines against variants of concern, but additional approaches are needed to ensure that we can stay one step ahead of the threat posed by these variants, other Betacoronaviruses, and potentially novel coronaviruses that have yet to emerge.
https://cepi.net/news_cepi/cepi-launches-funding-call-to-advance-development-of-broadly-protective-coronavirus-vaccines/

We've launched a $200million call to fund vaccines that are broadly protective against SARS-CoV-2 variants and other coronaviruses.

The first partnerships to be made through this Call will be announced in the coming weeks⤵️ https://t.co/7qcD4WxxK1

— CEPI (@CEPIvaccines) October 8, 2021